Patients
We retrospectively analyzed data pertaining to patients with refractory
(defined as inadequate response to treatment that included at least 4
cycles of ≥2 chemotherapeutic agents, including an alkylator and a
platinum-containing compound) or relapsed neuroblastoma who underwent
IREC therapy at the Nagoya University Hospital between October 2013 and
March 2020. Written informed consent for treatment with the IREC regimen
was obtained from the patients or their parents prior to the start of
chemotherapy. This study was approved by the ethics committee of the
Nagoya University Graduate School of Medicine and was conducted in
accordance with the principles of the Declaration of Helsinki.